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1.371 for the 6MV beams, TrueBeam and Versa HD, 
respectively. The same figure for the 10MV beams were 
1.484-1.524, and 1.501-1.543. Concerning beam penetration, 
TPR20,10 for 6 and 10 flattened and FFF TrueBeam beams 
were: 0.665, 0.629 (6MV) and 0.738, 0.703 (10MV), while for 
Versa HD beams are: 0.684, 0.678 (6MV) and 0.734, 0.721 
(10MV). 
 
Conclusion: Renormalization factor and unflatness 
parameters proved to be efficient to describe the FFF beam 
characteristics. Renormalization factors here presented could 
be used for all TrueBeam and Versa HD beams, without the 
need of recalculate them for the site specific conditions. 
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Purpose or Objective: Monte Carlo calculations are 
increasingly applied as an independent QA tool for pre-
treatment verification of patient plans for complex 
treatment delivery techniques such as VMAT. The dose 
obtained is usually imported to the treatment planning 
system for further analysis. The analysis can encompass 
visual comparison of dose distributions as well as qualitative 
and/or quantitative comparison of Dose Volume Histograms 
for specific structures. More sophisticated quantitative 
comparison in 3D includes gamma analysis combining dose 
difference and distance-to-agreement evaluation generating 
pass/fail maps. The normalized dose difference (NDD) 
method is considered to be an extension of the gamma-index 
concept including locally defined, spatially varying 
normalization factors. The NDD is reported to be insensitive 
to the dose grid size. Also, it shows which dose distribution 
has a higher value at the comparison point (has a sign).  
The objective of the work is to test the applicability of the 
NDD method in the Monte Carlo pre-treatment QA procedure, 
as well as to develop a stand-alone module which will include 
visual and quantitative analysis. 
 
Material and Methods: Monte Carlo simulations were 
performed using the EGSnrc/BEAMnrc code system with 
modifications, capable to compute dose distributions due to 
a continuously moving gantry, dynamic multileaf collimator 
and variable dose rate (I.A. Popescu and J. Lobo, Radiother. 
Onc.2007). A Monte Carlo model of a Varian Clinac iX 
accelerator was used. Patient treatment plans were 
generated by Eclipse treatment planning system (Varian 
Medical Systems, USA) and calculated by the AAA algorithm. 
NDD formalism has been applied in Matlab (Mathworks®) as 
described in (Jiang SB, et al. Phys Med Biol 2006). 
 
Results: Dose distributions for patients in different 
anatomical regions have been obtained; pelvic and head and 
neck. Example of NDD analysis for a prostate cancer is shown 
in the figure.  
 
 
 
A 3%, 3 mm tolerance criteria is used. The colour scale varies 
from ±3%, i.e. the region of acceptance. Negative values 
indicate that the Eclipse dose (AAA) is lower than the Monte 
Carlo calculated dose. The Monte Carlo simulations include 
the air surrounding the patient. Therefore the NDD values 
outside the patient are negative. All the NDD values are 
within tolerance on the left transversal slice, i.e. there is 
agreement between Monte Carlo and AAA. On the right 
transversal slice, the AAA shows higher target dose in small 
ventral regions and lower dose at some points in the risk 
organ (rectum). In general the pass-rate observed is > 95%. A 
slight dominance of the Monte Carlo dose has been observed 
in the NDD statistics expressed as a shift of the maximum in 
the NDD distribution. 
 
Conclusion: The NDD method can give important information 
for pre-treatment verification of VMAT plans, which is 
complementary to the dose analysis in the treatment 
planning system. 
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Purpose or Objective: To evaluate the usefulness and 
accuracy of a commercially available plastic scintillator 
(Exradin W1) for use in in vivo proton therapy skin dosimetry. 
 
Material and Methods: Six patients undergoing passive 
scatter proton therapy for prostate cancer were enrolled in 
an IRB approved protocol. The Exradin W1 plastic scintillator 
was used to measure in vivo skin dose by attaching the 
detector to the patient’s skin at the central axis of each 
treatment field (2 laterally opposed treatment fields). 
Measurements were acquired once per week for the entire 
treatment course resulting in a total of 93 measurements. 
The detector was first calibrated on a Cobalt-60 unit, and 
phantom measurements in the proton beam with the W1 and 
a calibrated parallel plane ion chamber were used to account 
for the under-response due to ionization quenching. The 
average dose difference between the Exradin W1 in vivo dose 
and parallel plane ion chamber in phantom dose over all 
measurement and per-patient was computed, as well as 
standard deviations. Furthermore, dose extracted from the 
treatment planning system was compare to the parallel plane 
ion chamber. Finally, baseline stability measurements in the 
cobalt unit were performed weekly for the duration of the 
study. 
 
Results: The calibrated detector exhibited a 7% under-
response for 225 MeV proton beams. The temperature under-
response was 4% when used at 37° C (relative to the response 
at the calibration temperature of 20° C). The detector 
exhibited a stable response and was within 1% for the 
duration of the study (144 days). The average dose difference 
between the Exradin W1 and parallel plane ion chamber over 
all patient measurements was 0.27 ± 0.67% after applying the 
temperature and quenching correction factors. The dose 
difference between the Exradin W1 in vivo measurements 
and parallel plane ion chamber for all six patients treatment 
fields throughout the study were all within ± 2% with a 
standard deviation of 0.67% (see figure 1). 
 
Figure 1 Dose difference between Exradin W1 in vivo dose 
and parallel plane ion chamber dose for every patient during 
the study. 
 
